Featured Research

from universities, journals, and other organizations

Advance in manipulating T-cells

Date:
October 10, 2012
Source:
University of Massachusetts Amherst
Summary:
Until recently, medical researchers had little hope of manipulating nave T cells to study their crucial roles in immune function because they were largely impenetrable. Now, researchers have made a master key, able to get into nave T cells to deliver bio-active cargo such as synthetic molecules.

Scientists have found a way not only to get inside nave T cells, but to deliver bio-active cargo such as proteins and synthetic molecules across that long-locked cell membrane, by using a new synthetic protein transduction domain (PTD) that mimics natural ones.
Credit: Image courtesy of University of Massachusetts Amherst

Until recently, medical researchers had little hope of experimentally manipulating nave T cells to study their crucial roles in immune function, because they were largely impenetrable, says polymer scientist Gregory Tew of the University of Massachusetts Amherst: "So far off limits we could not readily get inside to investigate their workings."

Now, he and colleagues including immunologist Lisa Minter have found a way not only to get inside nave T cells, but to deliver bio-active cargo such as proteins and synthetic molecules across that long-locked cell membrane, by using a new synthetic protein transduction domain (PTD) that mimics natural ones. Tew and colleagues call their new macromolecules "PTD mimics" (PTDMs). They are able to slip through the T cell's membrane and deliver a payload of therapeutic small interfering RNA (siRNA).

The invention is "something like a master key, because we can get into cells without their permission, and into difficult-to-access cell types like human T cells," says Tew. "We think it will lead to new advances in fundamental immunology and it also holds great potential for therapeutic applications in the clinic. We hope every immunologist on the planet hears about this delivery breakthrough, because now they can begin to study T cell function in new ways."

Earlier methods required electroporation or the use of viruses, which either decrease cell viability or pose unacceptable risks to patients in a treatment setting, he adds. Tew and Minter's work appears in the current issue of Molecular Therapy.

T lymphocytes are a subset of white blood cells that play a critical role in cell-mediated immunity, fighting against invading infections, cancer and HIV, for example. There are several different types of T cells, so named because they mature in the thymus gland. For years, scientists have wanted to study nave T cells in particular, those that can respond to pathogens the immune system has not yet seen.

Tew, Minter and colleagues saw an unmet need for non-viral, efficient and easily prepared reagents for use in delivering siRNA into difficult-to-enter cell types such as human T cells. Successfully delivering siRNA into nave T cells would demonstrate efficient gene knockdown without toxicity and provide a powerful new immunologic tool.

The UMass Amherst team leaders say one of the things they tried to pioneer is being inspired by what nature does, then building synthetic mimics of that. "We felt that if we were not limited to the usual amino acid alphabet of proteins, we could do it better. That turned out to be true; we used biomimetic design principles to make PTDMs that are less toxic and more effective for moving cargo across the cell membrane than natural ones."

"What we modify is the chemical structure," Tew explains. "We've built the principles of a natural PTD into a new macromolecule that's bigger, longer, has more dense groups and different architecture. It slips into the T cell without damaging it, and can carry cargo, in this case siRNA, across that membrane."

They accomplished this by first identifying key features of natural PTDs, then capturing some of their chemical properties in new macromolecular synthetic polymer mimics. Specifically, they designed and studied two different PTDMs inspired by polyarginines and amphiphilic (able to cross both water and lipid membranes) peptides to deliver siRNA into two hard-to-transfect cell types: Cells from a line of immortalized human T lymphocytes and human peripheral blood cells from three different donors.

As one of several tests of effectiveness, they targeted knockdown of NOTCH1, a gene-controlling transmembrane receptor that also plays a role in T cell development, proliferation and differentiation. The authors report achieving 50 percent knockdown of NOTCH1 protein expression in both cell types for up to 72 hours after one treatment.

"The T cell goes about its business. It looks normal except that it has much less NOTCH1," says Tew. "With this new tool, we expect we can fine-tune T cell activation. In the case of cancer surveillance, you may want to turn it up to stimulate immune responses, but with autoimmune diseases it would be beneficial to turn it down."

This work was funded by grants from the National Science Foundation and the American Heart Association.


Story Source:

The above story is based on materials provided by University of Massachusetts Amherst. Note: Materials may be edited for content and length.


Cite This Page:

University of Massachusetts Amherst. "Advance in manipulating T-cells." ScienceDaily. ScienceDaily, 10 October 2012. <www.sciencedaily.com/releases/2012/10/121010171936.htm>.
University of Massachusetts Amherst. (2012, October 10). Advance in manipulating T-cells. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/10/121010171936.htm
University of Massachusetts Amherst. "Advance in manipulating T-cells." ScienceDaily. www.sciencedaily.com/releases/2012/10/121010171936.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins